Effect of aprepitant on the pharmacokinetics of intravenous midazolam

Journal of Clinical Pharmacology

Volumn 47, Issue 6, 2007, Pages 744-750

  Majumdar, Anup K ^a   Yan, Kerri X ^a   Selverian, Diana V ^a   Barlas, Suna ^a   Constanzer, Marvin ^a   Dru, James ^a   McCrea, Jacqueline B ^a   Ahmed, Tuli ^a   Frick, Glen S ^b   Kraft, Walter K ^b   Petty, Kevin J ^a   Greenberg, Howard E ^b,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c American College of Clinical Pharmacology   (United States)

Author keywords

Aprepitant; CYP3A4 interaction; Intravenous; Midazolam; Pharmacokinetics

Indexed keywords

APREPITANT; MIDAZOLAM;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISORIENTATION; DIZZINESS; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG MONITORING; FATIGUE; FEMALE; GEOMETRY; HUMAN; MALE; NORMAL HUMAN; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANTIEMETICS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MORPHOLINES;

EID: 34249021946     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007300807     Document Type: Article

References (11)

1. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. The Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003 ; 21: 4112-4119.
2. Poli-Bigelli S., Rodrigues-Pereira J., Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003 ; 97: 3090-3098.
3. Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the Substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 ; 32: 1287-1292.
4. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. J Clin Pharmacol. 2003 ; 43: 443-469.
5. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther. 2003 ; 74: 150-156.
6. Constanzer ML, Chavez-Eng CM, Dru J., Kline WF, Matuszewski BK Determination of a novel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors. J Chromatogr B. 2004 ; 807: 243-250.
7. EMEND capsules (aprepitant) [product label]. West Point, Pa: Merck ; 2006.
8. Nygren P., Hande K., Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005 ; 55: 609-616.
9. Xie R., Tan LH, Polasek EC, et al. CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations. J Clin Pharm. 2005 ; 45: 352-356.
10. Gan TJ, Apfel C., Kovac A., Philip B., Lawson F. The NK1 receptor antagonist aprepitant for prevention of postoperative nausea and vomiting [abstract]. Anesthesiology. 2005 ; 103: A769.
11. Gan TJ, Apfel CC, Kovac A., et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg. In press.